Celldex Therapeutics, Inc. (CLDX)

Celldex Therapeutics experienced several significant stock events in the past six months. Positive clinical data from Phase 2 studies in chronic urticarias demonstrated improvements in patient quality of life. The company completed enrollment in global Phase 3 studies for Barzolvolimab in chronic spontaneous urticaria ahead of schedule and initiated a global Phase 3 study in cold urticaria and symptomatic dermographism. Celldex announced and closed a $300 million public offering of common stock. The company's share price increased by 110.92% between April 10, 2025, and April 9, 2026.

As a clinical-stage biopharmaceutical company, Celldex Therapeutics' revenue is primarily derived from collaborations or grants, rather than direct product sales to consumers. Its market valuation is heavily influenced by clinical trial milestones, regulatory progress, and research and development activities. Therefore, traditional demand seasonality is not directly applicable to Celldex Therapeutics at this stage.

Celldex Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on mast cell biology and developing therapeutic antibodies for severe inflammatory, allergic, autoimmune, and other diseases. Their major product candidates include Barzolvolimab (CDX-0159) for mast cell-driven diseases and CDX-622, a bispecific candidate for inflammatory diseases.

Celldex Therapeutics is headquartered in Hampton, New Jersey, United States. The company has a broad global reach in its clinical development, having completed enrollment in large-scale international Phase 3 trials for Barzolvolimab, involving over 1,900 patients across 43 countries, indicating a substantial global market potential.

Celldex Therapeutics has maintained a positive brand reputation over the past year due to strong clinical progress and positive trial results for Barzolvolimab. Consistent positive Phase 2 results for Barzolvolimab in chronic spontaneous urticaria, cold urticaria, and symptomatic dermographism have demonstrated significant efficacy and improvements in patient quality of life. The rapid completion of enrollment in global Phase 3 studies for Barzolvolimab in CSU underscores the medical community's interest. Celldex's dedication to developing therapies for severe inflammatory, allergic, and autoimmune disorders positions it as an innovator in addressing significant unmet medical needs.

Celldex Therapeutics, Inc. has significant institutional ownership, with 187 institutional owners and shareholders holding a total of 71,907,640 shares. Wellington Management Group Llp, Kynam Capital Management, LP, and BlackRock, Inc. are among the major institutional owners. Thomas S. Paluck is the largest individual shareholder, owning 7.63 million shares, representing 11.47% of the company.